Journal of Clinical Oncology, Vol 5, 1607-1612, Copyright © 1987 by American Society of Clinical Oncology

ARTICLES

Long-term survival of advanced refractory ovarian carcinoma patients with small-volume disease treated with intraperitoneal chemotherapy

SB Howell, S Zimm, M Markman, IS Abramson, S Cleary, WE Lucas and RJ Weiss
Department of Medicine, University of California, San Diego, La Jolla 92093.

Ninety ovarian carcinoma patients failing primary intravenous (IV) combination chemotherapy were treated with cisplatin-based combination intraperitoneal therapy. Sixty-five patients had residual disease greater than 2 cm at the start of intraperitoneal therapy. Their median survival was 8 months. Twenty-five patients had disease less than 2 cm; their median survival was greater than 49 months, and the survival curve has an apparent plateau at 69%, with no relapses having occurred after 32 months. The median survival for all 90 patients was 15 months. The median duration of follow-up for all patients was 37 months. These results confirm the critical role of tumor bulk in determining the effectiveness of intraperitoneal therapy, and suggest a role for intraperitoneal salvage treatment in patients with small-volume disease.
CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				M. Markman and J. L. Walker Intraperitoneal Chemotherapy of Ovarian Cancer: A Review, With a Focus on Practical Aspects of Treatment J. Clin. Oncol., February 20, 2006; 24(6): 988 - 994. [Full Text] [PDF]

				M. Markman Point: Intraperitoneal Chemotherapy in the Management of Ovarian Cancer J Natl Compr Canc Netw, November 1, 2004; 2(6): 549 - 554. [Abstract] [PDF]

				M. Markman Role of Intraperitoneal Chemotherapy in the Front-Line Setting J. Clin. Oncol., May 15, 2003; 21(90100): 145s - 148. [Abstract] [Full Text] [PDF]

				G. A. Sarosy and E. Reed Autologous Stem-Cell Transplantation in Ovarian Cancer: Is More Better? Ann Intern Med, October 3, 2000; 133(7): 555 - 556. [Full Text] [PDF]

				D. S. Alberts, P.Y. Liu, E. V. Hannigan, R. O'Toole, S. D. Williams, J. A. Young, E. W. Franklin, D. L. Clarke-Pearson, V. K. Malviya, B. DuBeshter, et al. Intraperitoneal Cisplatin plus Intravenous Cyclophosphamide versus Intravenous Cisplatin plus Intravenous Cyclophosphamide for Stage III Ovarian Cancer N. Engl. J. Med., December 26, 1996; 335(26): 1950 - 1955. [Abstract] [Full Text] [PDF]

				J. H Kearsley Some basic guidelines in the use of chemotherapy for patients with incurable malignancy Palliative Medicine, January 1, 1994; 8(1): 11 - 17. [Abstract] [PDF]

				S. A. Cannistra Cancer of the Ovary N. Engl. J. Med., November 18, 1993; 329(21): 1550 - 1559. [Full Text]

				W. P. McGuire, E. K. Rowinsky, N. B. Rosenshein, F. C. Grumbine, D. S. Ettinger, D. K. Armstrong, and R. C. Donehower Taxol: A Unique Antineoplastic Agent with Significant Activity in Advanced Ovarian Epithelial Neoplasms Ann Intern Med, August 15, 1989; 111(4): 273 - 279. [Abstract] [PDF]